Clinical application of human embryonic stem cells.
10.5124/jkma.2011.54.5.454
- Author:
Hyung Min CHUNG
1
Author Information
1. CHA Stem Cell Institute of CHA University, Seoul, Korea. stem_chung@naver.com
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Human embryonic stem cells;
Cell therapy product;
Differentiation
- MeSH:
Adult;
Adult Stem Cells;
Alzheimer Disease;
Artificial Cells;
Biology;
Blindness;
Blood Cells;
Cell Transplantation;
Drug Discovery;
Embryonic Stem Cells;
Embryonic Structures;
Epithelial Cells;
Fetus;
Heart Failure;
Humans;
Induced Pluripotent Stem Cells;
Models, Animal;
Parkinson Disease;
Phenotype;
Placenta;
Retinaldehyde;
Spinal Cord Injuries;
Stem Cells;
Stroke;
Transplants
- From:Journal of the Korean Medical Association
2011;54(5):454-461
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recent advances in stem cell biology, including the development of optimized cell type-specific culture systems, and the broader understandings of biochemical and molecular signals involved in cell self-renewal and differentiation have brought cell-based therapy closer to practical application. As of now, at least 250 adult stem cell therapies are being used or tested in clinical situations. Stem cells have two important properties that distinguish them from other types of cells; they can both proliferate without changing their phenotypes indefinitely, and they also can differentiate into one or more new kinds of cells depending on their culture conditions. Thus, stem cell therapy could be most effective for treating the diseases that are marked by the loss of cells. The typical examples are Parkinson's disease, Alzheimer's disease, diabetes, heart failure, blindness, spinal cord injury, and stroke. Additionally, stem cell derivatives can be used in drug discovery as well. In the last decade, various types of stem cells have been identified from preimplantation stage embryos, fetuses, placentas, and adult tissues. Moreover, it is now almost a common practice to produce induced pluripotent stem (iPS) cells from various adult somatic cells using only a few defined factors. Thus, it is feasible that patient-specific stem cells will be generated with less controversy in the near future. However, human embryonic stem (ES) cells firmly remain "the gold standard" because of their greatest potential to become any type of cell in the body. The vast knowledge obtained from human ES cell research in the past decade has made cell-based therapy more promising than ever. Even the recent establishment of iPS cell technology is the culmination of human ES cells research. In our laboratory, interesting human cardiovascular cells including endothelial precursor cells and beating myocardiac cells, artificial blood cells, and retinal pigment epithelial cells were successfully differentiated and their therapeutic potential was confirmed after cell transplantation into animal models. Thus, here, the current research status of human embryonic stem cell-based therapy will be introduced and the future directions of stem cell applications in clinical trials will be discussed.
